A Long-term Follow-up Study of Patients Who Received MB-105

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07340814

Enrollment

Registered

2026-01-14

Start date

2026-02-27

Completion date

2040-10-15

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Any Patient Treated With MB-105

Brief summary

This study is to fulfil the regulatory requirement for 15-year follow-up for patients treated with MB-105 in any study

Detailed description

This study is for long term follow up of efficacy and safety for any patient treated with MB-105 who has consented to joining the LTFU study. There are no exclusion criteria.

Interventions

BIOLOGICALMB-105

This is an observational study with no study product administered because it is the LTFU study for patients who received the product in another study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

Received MB-105 Signed informed consent Agree to transfer of samples from previous study Able to comply with study requirements

Exclusion criteria

N/A

Design outcomes

Primary

Measure	Time frame	Description
Assess long term safety of MB-105 in patients who received MB-105	15 Years	SAEs

Secondary

Measure	Time frame	Description
Assess long term efficacy of MB-105 in patients who received MB-105	15 Years	Time to progression/relapse in those who have not yet relapsed and overall survival

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026